3386 Stock Overview
Engages in the manufacture, marketing, sale, import, and export of life science research biotools worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Cosmo Bio Company,Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,117.00 |
| 52 Week High | JP¥1,229.00 |
| 52 Week Low | JP¥888.00 |
| Beta | 0.23 |
| 1 Month Change | -2.95% |
| 3 Month Change | 4.00% |
| 1 Year Change | 12.83% |
| 3 Year Change | 11.37% |
| 5 Year Change | 10.59% |
| Change since IPO | -44.98% |
Recent News & Updates
Recent updates
Cosmo Bio Company,Limited's (TSE:3386) Popularity With Investors Is Under Threat From Overpricing
Apr 15
Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 12Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital
May 09Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why
Mar 23Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?
Feb 07
Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?
Jan 17Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?
Dec 23Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?
Dec 02Shareholder Returns
| 3386 | JP Healthcare | JP Market | |
|---|---|---|---|
| 7D | 2.6% | 6.6% | 6.3% |
| 1Y | 12.8% | -7.6% | -5.8% |
Return vs Industry: 3386 exceeded the JP Healthcare industry which returned -8.8% over the past year.
Return vs Market: 3386 exceeded the JP Market which returned -6.5% over the past year.
Price Volatility
| 3386 volatility | |
|---|---|
| 3386 Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 3.0% |
Stable Share Price: 3386 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 3386's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 174 | Norihiko Shibayama | www.cosmobio.co.jp |
Cosmo Bio Company,Limited engages in the manufacture, marketing, sale, import, and export of life science research biotools worldwide. The company distributes antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, bacteria, and others, as well as detection reagents, cell and tissue culture systems, gene analysis systems, and others; and research instruments, including electrophoresis apparatuses, cell culture labware, gene manipulation systems, data analysis software, and others. It also provides drug discovery and custom research services; clinical diagnostics; consigned services, such as intestinal flora analysis, tear fluid analysis, and cell assays services; and custom peptide synthesis and antibody production.
Cosmo Bio Company,Limited Fundamentals Summary
| 3386 fundamental statistics | |
|---|---|
| Market cap | JP¥6.37b |
| Earnings (TTM) | JP¥262.00m |
| Revenue (TTM) | JP¥10.04b |
24.3x
P/E Ratio0.6x
P/S RatioIs 3386 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3386 income statement (TTM) | |
|---|---|
| Revenue | JP¥10.04b |
| Cost of Revenue | JP¥6.71b |
| Gross Profit | JP¥3.33b |
| Other Expenses | JP¥3.07b |
| Earnings | JP¥262.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 09, 2025
| Earnings per share (EPS) | 45.95 |
| Gross Margin | 33.17% |
| Net Profit Margin | 2.61% |
| Debt/Equity Ratio | 0.2% |
How did 3386 perform over the long term?
See historical performance and comparisonDividends
4.5%
Current Dividend Yield111%
Payout RatioDoes 3386 pay a reliable dividends?
See 3386 dividend history and benchmarks| Cosmo Bio CompanyLimited dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2025 |
| Dividend Pay Date | Sep 10 2025 |
| Days until Ex dividend | 71 days |
| Days until Dividend pay date | 146 days |
Does 3386 pay a reliable dividends?
See 3386 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 05:37 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Bio Company,Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.